Cytena secures €3M in funding to advance its single-cell technology
By Nikita Chaurasia  Date: 2019-03-27

Cytena secures €3M in funding to advance its single-cell technology
  • The capital will help to broaden the sales activities of Cytena and capitalize on new applications
  • Single-cells are used in the development of biopharmaceuticals and in stem cell and cancer research

Reports confirm that High-Tech Grunderfonds (HTGF) and two private investors are going to invest another 3 million euros in Cytena GmbH. This capital will be used in developing Cytena’s single-cell printer lab technology, broaden its sales activities and promptly tap into the capabilities of new applications.

Apparently, the two private investors and High-Tech Grunderfonds (HTGF) have confidence in the significance of isolation of single-cell for the development of biopharmaceuticals as well as for genetic analysis in diagnostics and research.

Benjamin Steimle, CFO of Cytena stated that the new capital would help to understand better and serve the customer’s requirements as well as help to increase the market share of the company.

Cytena mentioned that along with way, important milestones achieved include a collaboration in sales with a vital American company and addition of x.sight devices.

In recent years, the analysis of individual biological cells has gained its importance rapidly. These single-cells are used in the development of latest drugs called biopharmaceuticals and also in stem cell and cancer research, the firm said.

Cytena’s single cell printers comprise of laboratory devices for sorting and managing individual viable cells. These instruments are considered as one of the innovative platforms for life science and offer long-term contribution towards the manufacturing and development of new drugs.

According to HTGF Investment Manager, Dr. Lena Krzyzak, investment in the Series A round helps the company to continues its successful growth in start-up financing. Dr. Krzyzak said with the company is greatly confident in its management team’s ability to expand the market and product development.

For the uninitiated, Cytena is a well-known start-up in life sciences which was founded in 2014 at the University of Freiburg, by spinning off from the Institute for Microsystems Technology (IMTEK). The Cytena team has developed the technology called the single-cell printer which enables the isolation of single cells in a gentle, sterile and documented process.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Insight unveils new Tech Journal for small & midmarket businesses
Insight unveils new Tech Journal for small & midmarket businesses
By Nikita Chaurasia

Insight Enterprises, a renowned US-based technology company and an integrator of the Insight Intelligent Technology SolutionsTM for companies of all sizes, reportedly unveiled a new magazine titled Tech Journal. This magazine would be published each...

Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
By Nikita Chaurasia

U.S. auto giant Tesla, Inc.’s CEO, Elon Musk has recently made headlines when he announced that his company is planning to develop ventilators for COVID-19 patients. The move comes after the United States government’s latest appeal for do...

Google News launches Project Oasis to support local entrepreneurs
Google News launches Project Oasis to support local entrepreneurs
By Nikita Chaurasia

Google News has apparently launched Project Oasis in partnership with the University of North Carolina, Table Stakes co-founder Doug Smith, and LION Publishers. The partnership is aimed at helping the founders and aspiring founders of digital ne...

Pfizer collaborates with BioNTech to develop coronavirus vaccine
Pfizer collaborates with BioNTech to develop coronavirus vaccine
By Nikita Chaurasia

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNT...

Amplitude completes debut acquisition with ClearBrain buyout
Amplitude completes debut acquisition with ClearBrain buyout
By Nikita Chaurasia

Amplitude, a comprehensive product intelligence company, announced that it has acquired the software company ClearBrain to accelerate big product bets. The acquisition will enable customers of the company to estimate about the revenue growth driving ...